Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.59 |
| ▸ | KDR | P35968 | 5/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | FYN | P06241 | 2/20 | 0.59 |
| ▸ | YES1 | P07947 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324271 | 0.92 | SRC (0.72) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6692340 | 0.90 | SRC (0.70) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6330107 | 0.88 | SRC (0.76) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6327691 | 0.87 | SRC (0.72) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6320866 | 0.85 | SRC (0.76) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL5576888 | 0.83 | SRC (1.00) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL5576890 | 0.83 | SRC (1.00) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6692335 | 0.82 | SRC (0.98) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6695629 | 0.79 | SRC (0.55) | SRCPDGFRBFGFR1KDRLCK | |
| SCHEMBL6696431 | 0.79 | SRC (0.98) | SRCPDGFRBFGFR1KDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | SRC 67/4885PDGFRB 575/4885FGFR1 525/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | SRC 67/4885PDGFRB 575/4885FGFR1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.